All News
Phase 3 Trials of Baricitinib Disappoint in SLE
Despite the encouraging phase II trial results of baricitinib in systemic lupus erythematosus (SLE) patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE, thereby halting development of baricitinib in SLE.
Read Article
An Alternative Pain Protocol Following Knee Replacement Surgery
d
EurekAlert!
A study led by Vinod Dasa, MD, Professor of Orthopaedics at LSU Health New Orleans School of Medicine, reports that a novel surgical pain management strategy following total knee arthroplasty (TKA), or total knee replacement, provided pain relief without opioids.
Read Article
The Late Edition (2.24.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Check out our latest podcast--The Late Edition.
https://t.co/DnIAuci11I https://t.co/Xd4tN5VajI
Links:
Dr. John Cush RheumNow ( View Tweet)
Periodontal Mucosal Breaks Trigger RA Disease Activity
Periodontal disease (PD) is more common in RA, especially those with anti-citrullinated protein antibodies (ACPAs). RA activity has been linked to the severity of PD and mucosal inflammation.
https://t.co/eTDNqlOHyp https://t.co/VZoeqJmsr0
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 25 studies, betw 1985 - 2021, showed US average annual visits for RA=5.25 for US rheums (vs 3.3 ex-US) & 4.8 US non-rheums. SLE=3.24 & 12.3 for US non-Rheums. FM=1.8 for US rheums & 0.4 vs ex-US Rheums. Rheum Visits Decreased 1982 to 2019 https://t.co/WIXDXUCG60 https://t.co/s7W9gcd5dd
Links:
Dr. John Cush RheumNow ( View Tweet)
5 Nordic register study of new b/tsDMARD starts in in PsA - 5659 ADA (56% biologic-naïve) & 4767 other b/tsDMARD (21% naïve) starts. ADA more often 1st line; newer b/tsDMARDsin biologic-experienced. 2nd line retention: ADA 65%, ABA 45%, Otez 43%. https://t.co/XKLiana6vB https://t.co/PotwYlYXto
Links:
Dr. John Cush RheumNow ( View Tweet)
National study of 184,722 #RA pts (182 RISE sites) shows High % of socially deprived, high comorbidity, Medicaid- RA pts mainly in the south; <10% of Rheum practices cared for >50% of Medicaid RA pts. Moderate correlation betw comorbidity & Dz activity https://t.co/dsjH78cJqp https://t.co/U3l2m566d1
Links:
Dr. John Cush RheumNow ( View Tweet)
Chest Pain & Fever
Lessons from the clinic, brought to you by https://t.co/4UQlqwujiR March 18 &19, 2023 - Dallas, TX
https://t.co/6iMT1Tt7KR https://t.co/owui66FMPJ
Dr. John Cush RheumNow ( View Tweet)
Comparing ACR21 vs EULAR22 RA Guidelines
https://t.co/dLtEaUBTKM https://t.co/Rang58z2N2
Links:
Dr. John Cush RheumNow ( View Tweet)
Overview of Juvenile idiopathic arthritis (JIA) assoc uveitis (JIA-U) seen in 10–15% ofJIA pts, higher risk w/ ANA+, oligo-JIA, f& onset ≤6 yrs age. Rx options: topical steroids, MTX, ADA, INFLX, RTX and TCZ (review of TCZ in JIA-U) https://t.co/fqQ8ZhSLCM https://t.co/1GkUpCqJoE
Links:
Dr. John Cush RheumNow ( View Tweet)
Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars
- majority say economics arent favorable to switch to biosimilar
- Yet majority "very to somewhat” comfortable w/ biosimilars
- US: Slow biosimilar uptake due to disappointing costs https://t.co/DOhrfELssY https://t.co/f2iy9igq5d
Links:
Dr. John Cush RheumNow ( View Tweet)
Im not sure this was necessary but - a metanalysis of 10 RCTs w/ 847 OA patients shows colchicine use in osteoarthritis had no efficacy as far as pain reduction (vs control; SMD= 0.17) & no improvement in function (SMD, - 0.37) https://t.co/pDR0XO6vCg https://t.co/o8yYByBj8I
Links:
Dr. John Cush RheumNow ( View Tweet)
Specific ACPAs and Autoantibodies Lead to RA-Associated ILD
https://t.co/AuTDGt8gYJ https://t.co/Q1rKdxkbLZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Vision Loss with ANCA-Associated Vasculitis
Shelley K. Dhillon, MD, presents her poster at RWCS 2023.
https://t.co/wE76hDJq4y https://t.co/pbuH4SBTSp
Links:
Dr. John Cush RheumNow ( View Tweet)
Subscribe to the RheumNow podcast on your favorite podcast app to get automatic downloads of the latest content. Listen in the car, airplane, anywhere! Rate, review and subscribe!
https://t.co/3EENe1VFKl https://t.co/V0X5BAtDBq
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparing ACR21 vs EULAR22 RA Guidelines
https://t.co/sqYLrg9wC2 https://t.co/y3a8yDVQhP
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Arthralgia, Raynaud's & Anemia
https://t.co/2H9EAZvP2s https://t.co/Bcerjoucjf
Links:
Dr. John Cush RheumNow ( View Tweet)
A Singular Case of Plural Effusion
Shashank Suresh, MD, presents his poster at RWCS 2023.
https://t.co/xAR2WcK9MN https://t.co/KVGM9ri3cj
Links:
Dr. John Cush RheumNow ( View Tweet)
Which Meds are Best for Acute Low Back Pain?
Acute low back pain (LBP) is a common cause of disability. An analysis in the Journal of Orthopaedic Research examined which non-opioid drugs are best for treating this condition.
https://t.co/StteWi87Y5 https://t.co/9CvYIqx5Cv
Links:
Dr. John Cush RheumNow ( View Tweet)